help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koch, C. A.
Right arrow Articles by Clement, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koch, C. A.
Right arrow Articles by Clement, S. C.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Carcinoid Tumors
*Cervical Cancer
The Journal of Clinical Endocrinology & Metabolism Vol. 84, No. 11 4209-4213
Copyright © 1999 by The Endocrine Society

Special Articles

Carcinoid Syndrome Caused by an Atypical Carcinoid of the Uterine Cervix

Christian A. Koch, Norio Azumi, Mary A. Furlong, Reena C. Jha, Theresa E. Kehoe, Catherine H. Trowbridge, Thomas M. O’Dorisio, George P. Chrousos and Stephen C. Clement

Developmental Endocrinology Branch, National Institute of Child Health and Human Development (C.A.K., G.P.C.), National Institutes of Health, Bethesda, Maryland 20892; Departments of Endocrinology and Metabolism (T.E.K., C.H.T., S.C.C.), Pathology (N.A., M.A.F.), and Radiology (R.C.J.), Georgetown University Medical Center, Washington, DC 20020; and Department of Endocrinology and Metabolism (T.M.O.), The Ohio State University Medical Center, Columbus, Ohio 43210

Address correspondence and requests for reprints to: Christian A. Koch, M.D., Developmental Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Building 10, Room 10N262, 10 Center Drive, MSC 1862, Bethesda, Maryland 20892-1862.


   Abstract
Top
 Abstract
Introduction
 Methods
 Case report
 Discussion
 References
 
Neuroendocrine tumors of the cervix are rare and are often under- or misdiagnosed. Because these tumors are very aggressive, early diagnosis and subsequent treatment are warranted. We describe a 46-yr-old woman with carcinoid syndrome caused by an atypical carcinoid of the uterine cervix. At age 44, she had dysplasia on Pap smear and underwent total abdominal hysterectomy with the diagnosis of adenocarcinoma. Fourteen months postoperatively, she developed the carcinoid syndrome and was found to have numerous liver metastases. Histological and immunohistochemical investigations of biopsy specimens from the patient’s liver lesions and original cervical lesion ("adenocarcinoma") suggested that this woman had a primary atypical carcinoid of the uterine cervix with metastases to the liver. Treatment with octreotide and alkylating agents decreased the episodes of flushing and diarrhea within 8 weeks. If an adenocarcinoma of the uterine cervix is diagnosed, atypical carcinoid should be in the differential diagnosis. Symptoms of the carcinoid syndrome should be pursued and, if present, a urinary 5-hydroxyindolacetic acid level should be obtained. Timely diagnosis of a neuroendocrine tumor of the cervix may improve survival.


   Introduction
Top
 Abstract
 Introduction
Methods
 Case report
 Discussion
 References
 
NEUROENDOCRINE tumors of the uterine cervix describe cervical neoplasms that show the histological characteristics of carcinoids, including argyrophilia and/or argentaffinnia, and immunoreactivity for chromogranin, synaptophysin, and neuron-specific enolase (1). Incidence, clinicopathological features, biological behavior, and natural history of these tumors have been difficult to estimate because various descriptive terms have been used for their broad morphologic spectrum. A recent consensus conference suggested four general categories of neuroendocrine tumors of the uterine cervix, analogous to pulmonary neuroendocrine tumors: typical (classical) and atypical carcinoid tumors, large cell neuroendocrine carcinomas, and small (oat) cell carcinomas (2).

Characteristic endocrine syndromes associated with neuroendocrine tumors of the cervix are rare (3, 4, 5, 6, 7, 8), with the carcinoid syndrome being extremely unusual (9, 10). Here, we describe a woman with carcinoid syndrome caused by an atypical carcinoid of the uterine cervix.


   Methods
Top
 Abstract
 Introduction
 Methods
Case report
 Discussion
 References
 
Tissue processing and histology

Specimens of the radical hysterectomy and liver core biopsies were fixed in 10% buffered formalin. Representative sections of the cervix and the entire liver core biopsies were routinely processed for paraffin embedding and stained with hematoxylin and eosin (H and E) for histopathological evaluation.

Immunohistochemical analysis

Paraffin-embedded sections of liver and cervix were immunohistochemically characterized with antibodies to chromogranin (dilution, 1:1500; Roche Molecular Biochemicals, Indianapolis, IN), synaptophysin (dilution 1:100; BioGenex Laboratories, Inc., San Ramon, CA), pan-keratin cocktail (prediluted; Ventana Medical Systems, Tucson, AZ), carcinoembryonic antigen (CEA) (dilution 1:50; DAKO Corp., Carpinteria, CA), vimentin (prediluted; Ventana Medical Systems), and S-100 protein (dilution 1:50; Zymed Laboratories, Inc., San Francisco, CA). Bound antibodies were detected by a standard avidin-biotin complex method with a peroxidase and diaminobenzidine color development system.

Hormonal measurements

Urinary 5-hydroxyindolacetic acid (5-HIAA) was measured by high-pressure liquid chromatography (American Medical Laboratories, Chantilly, VA). RIA was used for the following hormones measured in plasma: substance P, pancreastatin (Endocrine Research Laboratories, The Ohio State University Medical Center, Columbus, OH), ACTH, gastrin, ß-human chorionic gonadotropin (HCG), insulin-like growth factor I (IGF-I) (American Medical Laboratories); pancreatic polypeptide (PP), glucagon, vasoactive intestinal polypeptide (VIP) (Mayo Medical Laboratories, Rochester, MN), and somatostatin (Nichols Institute Diagnostics, San Juan Capistrano, CA).


   Case report
Top
 Abstract
 Introduction
 Methods
 Case report
Discussion
 References
 
A 46-yr-old Caucasian woman presented to us with nausea, vomiting, diarrhea, and paroxysmal episodes of flushing. She was nulligravida and denied drinking alcohol or smoking. Her family history revealed diabetes mellitus but no other endocrine disorders. She was healthy until age 44, when she underwent a routine Pap smear that was abnormal (dysplasia). A subsequent biopsy of the cervix revealed adenocarcinoma in situ. The patient underwent a total abdominal hysterectomy, bilateral salpingo-oophorectomy, and pelvic and paraaortic lymph node dissection. Twenty-two regional lymph nodes were negative. Intraoperatively, the appendix, right pericolic gutter, right hemidiaphragm, liver, gallbladder, lesser sac, stomach, omentum, left hemidiaphragm, spleen, pancreas, kidneys, small and large bowel, and the periaortic nodal chain were macroscopically and on palpation normal. The uterus was slightly enlarged without a recognizable tumor. H and E-stained sections of the cervix showed invasive, moderately well differentiated adenocarcinoma as a well-defined nodule measuring ~0.6 cm (Fig. 1AGo). An in situ component was identified in several sections. The tumor showed diffuse sheets with focal trabecular and focal tubular formation. The nuclei were oval to round, medium-sized showing a vesicular chromatin pattern with inconspicuous nucleoli. Mitosis were readily encountered. Postoperatively, the patient received oral equine estrogen.



View larger version (160K):
[in this window]
[in a new window]
  		Figure 1. Atypical carcinoid. A, The primary endocervical tumor displays a vesicular nuclear chromatin pattern. Nuclear pleomorphism and mitotic activity are also apparent (H and E; original magnification, x200). B, Immunoperoxidase staining with antisynaptophysin (data not shown) and antichromogranin antibody confirms neuroendocrine differentiation of the cervical tumor (original magnification, x200). C, A trabecular pattern is evident in this specimen of a liver metastasis with brisk mitotic activity and nuclear pleomorphism (H and E; original magnification, x200). D, The specimen of a liver metastasis displays an intense positivity for synaptophysin (data not shown) and chromogranin similar to the endocervical tumor specimen (original magnification x200).

 
Following radical hysterectomy, the patient initially reported occasional episodes of flushing. Fourteen months postoperatively, she developed diarrhea, nausea, vomiting, a 20-lb weight loss, and worsening paroxysmal episodes of flushing involving the face, neck, and upper trunk. She denied palpitations, dizziness, cough, shortness of breath, and taking any medications other than promethazine and Premarin. Pertinent findings on physical examination were a blood pressure of 134/78 mm Hg, a regular pulse of 91 bpm with normal heart sounds, facial erythema without Cushingoid features and with otherwise normal skin color and turgor, moist mucous membranes, no signs of pellagra, a well healed midline abdominal scar, and hepatomegaly with tenderness of the right upper and lower abdomen. Abdominal computed tomography (CT) and magnetic resonance imaging (MRI) demonstrated hepatomegaly and numerous liver lesions. In addition, MRI revealed a 2.8 x 3.1-cm mass in the head of the pancreas with atrophy of the body and tail of the pancreas and dilatation of the pancreatic duct distal to the mass (Fig. 2Go). Small, ~1-cm-sized lymph nodes were seen in the porta hepatis and peripancreatic chain, with no evidence of retroperitoneal lymphadenopathy. Given these imaging findings, a primary pancreatic tumor, such as adenocarcinoma or an islet cell tumor, were considered the most likely diagnosis.



View larger version (83K):
[in this window]
[in a new window]
  		Figure 2. High-resolution MRI of the abdomen. A, T1-weighted spoiled gradient echo axial image of the liver and pancreatic head. There are multiple low signal lesions in the liver (open arrow) and a mass in the neck of the pancreas (closed arrow). B, T1-weighted spoiled gradient echo fat-saturated axial image at the same level shows clear demarcation of bright signal normal pancreatic head (short arrow) and low signal of the pancreatic neck mass (long arrow). The normal pancreas is bright in this sequence due to the presence of proteinaceous material in the acini. C, T2-weighted half-Fourier acquisition single-shot turbo spin-echo coronal image shows the hepatic lesions as bright signal foci scattered throughout the liver.

 
The pancreatic lesion was endoscopically biopsied, but results were inconclusive. CT-guided biopsies of the liver lesions revealed a moderately differentiated adenocarcinoma with a trabecular and tubular pattern with sclerosed stroma (Fig. 1CGo). Nuclei showed open chromatin with inconspicuous nucleoli and occasional mitotic figures. No foci of necroses were identified. The remainder of hepatic parenchyma was unremarkable. A colonoscopy, including the rectum, was normal. Stool cultures were negative. Given the recently worsening episodes of flushing and diarrhea, carcinoid syndrome was now suspected.

To search for a neuroendocrine tumor, the following laboratory tests were obtained: 124 mg 24-h urinary 5-HIAA [649 µmol; normal, 0–10 mg (<52 µmol)]. Plasma measurements revealed 482 pg/mL substance P [356 pmol/L; normal, <250 pg/mL (<185 pmol/L)], 219 pg/mL pancreastatin [43 pmol/L; normal, <213 pg/mL (< 42 pmol/L)], 27 pg/mL somatostatin [16 pmol/L; normal, 10–22 pg/mL (6–13 pmol/L)], 364 pg/mL PP [87 pmol/L; normal, <270 pg/mL (< 65 pmol/L)], and 38 pg/mL glucagon [38 ng/L; normal, <61 pg/mL (< 61 ng/L)]. Results of gastrin, ACTH, VIP, insulin-like growth factor-1, and ß-HCG were normal. In serum, {alpha}-fetoprotein was normal, CA-19-9, 794 U/mL (0–36 U), and carcinoembryonic antigen (CEA), 74.8 ng/mL (0–3 ng). Routine laboratory, including complete blood count, electrolytes, fasting blood glucose, lipase, blood urea nitrogen, and creatinine, was normal. Albumin was low with 2.9 g/dL (3.5–5.5 g/dL), and liver function tests were elevated with an alkaline phosphatase of 1058 U/L (39–117 U/L), aspartate aminotransferase of 142 U/L (0–65 U/L), alanine aminotransferase of 133 U/L (0–65 U/L), and total bilirubin of 1 mg/dL (0.3–1.1 mg/dL). Given the 12-fold elevation of 5-HIAA, a carcinoid tumor was considered most likely. A subsequent 7.8 mCi Indium111-pentetreotide (10 µg) scan (Octreoscan), however, was negative.

Immunohistochemistry was performed on the previously obtained liver core biopsy specimens to further elucidate the primary site for the metastatic tumor. Neuroendocrine differentiation was evident with 100% of cells reacting positively for chromogranin and synaptophysin (Fig. 1DGo). Reactivity for keratin was also diffusely positive. Reactivity for CEA was positive in the apical pattern in 80% of the tumor cells. Vimentin and S-100 protein were negative. The liver biopsy specimens were compared with the original cervical tumor specimen, morphologically and immunohistochemically. Although nuclear pleomorphism and mitotic activity were greater, and trabecular and tubular formation were less prominent in the cervical tumor, histology was similar. Immunohistochemistry of the original tumor showed neuroendocrine differentiation, as demonstrated by chromogranin and synaptophysin positivity (Fig. 1BGo). Because of the phenotypic and immunophenotypic similarity, both cervical and liver tumors were considered to be the same tumor (i.e., a primary atypical carcinoid tumor of the uterine cervix with metastases to the liver).

Because of the extensive metastases, the patient was considered inoperable. Subsequently, the patient received weekly chemotherapy with 75 mg/sqm cisplatinum (136 mg), 2.6 g/sqm 5-fluorouracil (4.73 g), and 500 mg/sqm leucovorin (940 mg). In addition, 100 mcg octreotide sc every 8 h was initially administered and then changed to 30 mg lanreotide sc given monthly. Within 3 weeks of treatment, the patient’s liver function tests improved and almost normalized after 8 weeks of therapy. Repeated abdominal MRI, however, showed liver and pancreatic head lesions unchanged in size. The patient reported less episodes of flushing and of diarrhea.


   Discussion
Top
 Abstract
 Introduction
 Methods
 Case report
 Discussion
References
 
Neuroendocrine tumors of the uterine cervix are uncommon, with a range of frequencies from less than 0.5 to 5% of cancers of the cervix (8, 11, 12). The etiology of these rare neuroendocrine tumors remains unknown. Because the normal endocervix contains as many as 20% of argyrophilic cells resembling endocrine cells (12, 13), neuroendocrine tumor formation may arise from these cells. On the other hand, neuroendocrine carcinomas often show evidence of nonneuroendocrine differentiation (14), suggesting that these tumors may develop multidirectionally from primitive stem cells.

Neuroendocrine tumors of the cervix show expression of neuroendocrine markers, often argyrophilia, and characteristic morphological features defined by electron and light microscopy. Among the carcinomas of the endocervix with neuroendocrine differentiation, small cell carcinomas are well-characterized (15). Non-small cell neuroendocrine carcinomas of the uterine cervix, however, have rarely been described and are probably under- or misdiagnosed (11, 16).

Although an adenocarcinoma of the uterine cervix can be associated with all four aforementioned categories of neuroendocrine tumors of the cervix, the misdiagnosis of moderately or poorly differentiated adenocarcinoma instead of carcinoid tumor can easily be made, if glandular differentiation within the neuroendocrine tumor, a separate component of nonneuroendocrine adenocarcinoma, adenocarcinoma in situ, or combinations thereof, are present. Typical cervical adenocarcinomas occasionally contain rare argyrophilic cells or focally express neuroendocrine markers (17, 18, 19). Pure cervical adenocarcinomas with neuroendocrine cells (19, 20, 21, 22), neuroendocrine cells in adenocarcinoma components (8, 23, 24, 25), and neuroendocrine carcinomas associated with adenocarcinoma (23, 24, 26, 27, 28) have been reported. Adenocarcinomas of the uterine cervix containing isolated endocrine cells (18) should not be included in any of the four categories of neuroendocrine tumors of the cervix (2).

In our patient, the diagnosis of atypical carcinoid was based on the cervix and liver tumors showing features such as increased mitotic activity, open nuclear chromatin with inconspicuous nucleoli, and strong positive reactivity for chromogranin and synaptophysin. In addition, our patient presented with the carcinoid syndrome and urinary levels of 5-HIAA 12 times above normal. The specificity of urinary 5-HIAA for carcinoid is reported to be between 88 and 100% (29, 30).

The carcinoid syndrome in neuroendocrine tumors of the cervix is very unusual. We are aware of only two other patients in whom oversecretion of 5-HIAA from a neuroendocrine cervical tumor may have caused or at least contributed to the carcinoid syndrome (9, 10). One was a 34-yr-old woman with metrorrhagia who developed facial flushing on palpation of her abdomen (9). Her 24-h urinary 5-HIAA levels were 52 mg and 198 mg, respectively. She had a 3-cm cervical tumor with lung and liver metastases, all being argentaffin. However, no other histochemical characteristics of carcinoid tumor were reported.

The second patient was a 38-yr-old woman who underwent a simple vaginal hysterectomy for menorrhagia (10). Histopathological examination showed carcinoid tumor. Abdominal CT demonstrated a low attenuation lesion of the liver. The patient developed paroxysmal facial flushing and diarrhea. Urinary 5-HIAA levels (24 h) were 145 and 237 µmol (normal, 0–58). ACTH was 262 pg/ml (<80), random serum cortisol was 1340 nmol/L (100–440), and ß-HCG was 502 IU/L (<5). Chemotherapy was initiated, but the patient died within 1 month.

The carcinoid syndrome most commonly occurs with tumors of the small intestine, appendix, and proximal colon (31). Its development is a function of tumor mass and extent of metastases, although even numerous liver metastases may not lead to the carcinoid syndrome (32). In the absence of hepatic metastases, the occurrence of the carcinoid syndrome is rare and depends on the release of mediators directly into the systemic circulation rather than the portal circulation. Potential mediators of the carcinoid syndrome are prostaglandins and vasoactive peptides such as substance P. Serotonin does not play an important role in mediating the carcinoid flush; urinary 5-HIAA levels do not correlate with the intensity of flushing (33, 34, 35).

In our patient, it remains unclear whether the initially occasional episodes of flushing that occurred after radical hysterectomy, were related to the carcinoid syndrome or merely due to estrogen/progesterone imbalance. The latter seems more likely because, at that time, our patient did not have visible liver metastases yet. However, it is possible that micrometastases in the liver or other sites with direct access to the systemic circulation could have caused the carcinoid syndrome. On the other hand, a primary carcinoid tumor other than the cervix, with direct secretion of its mediators into the systemic circulation also could have been responsible for the carcinoid syndrome. There are reports on carcinoid tumors including the appendix and ileum, with metastases to the cervix and corpus uteri (36). However, in our patient, the 1-yr latency period between radical hysterectomy and then rapid development and progression of liver metastases makes the diagnosis of a primary noncervical carcinoid tumor that initially metastasized to the cervix unlikely. Interestingly, the Indium111-pentetreotide scan (10 µg) was negative, although this scan reportedly has a sensitivity of 89% and specificity of 100% (37). In addition to the 2.8 x 3.1-cm large pancreatic mass, many of the liver metastases measured more than 2 cm on MRI and, thus, were big enough to be detected by the Octreoscan, if these lesions had possessed primarily somatostatin receptor subtypes 2, 3, and 5; however, the receptor status of the patient’s tumor remains unclear.

Although not related to clinical symptoms, the production of calcitonin (38), and the secretion of multiple hormones such as ß-melanocyte-stimulating hormone, serotonin, histamine, amylase (8), somatostatin, calcitonin, gastrin, VIP, and PP (39) have been reported in neuroendocrine tumors of the cervix. Besides high levels of 5-HIAA, CEA, and CA-19-9, our patient had mildly elevated levels of somatostatin and PP. Increased levels of CEA and CA-19–9 are commonly associated with liver and/or pancreatic disease (40).

Neuroendocrine carcinomas of the cervix are regarded as highly aggressive tumors (41) with subclinical hematogenous and lymphatic metastases frequently even in early disease. Neuroendocrine features in poorly differentiated carcinomas of the cervix indicate a poor outcome (17). Sixty-five percent of patients with cervical non-small cell neuroendocrine carcinomas die within 3 yr of diagnosis (15). Carcinoid tumor cells that stain positive for CEA, as in our patient, indicate a poor prognosis and often contain features of adenocarcinoma (31).

Treatment of neuroendocrine tumors of the cervix depends on the stage of the disease. In patients with inoperable metastatic carcinoid tumors, various chemotherapeutic regimens have been tried but none is associated with a good response. The average duration of remission remains below 1 year. Therapy with somatostatin analogs, such as octreotide and lanreotide, has resulted in reduction of the hormonal manifestations of the carcinoid syndrome (31, 42, 43), as shown in our patient.

In summary, a neuroendocrine tumor of the cervix, such as an atypical carcinoid, should be considered when an adenocarcinoma of the cervix is diagnosed. Clinical signs and symptoms of the carcinoid syndrome should be pursued. If carcinoid syndrome is suspected, a urinary 5-HIAA level should be obtained. Treatment of a cervical neuroendocrine tumor should be aggressive and directed toward the adenocarcinoma element (44).

Received June 16, 1999.

Accepted August 12, 1999.


   References
Top
 Abstract
 Introduction
 Methods
 Case report
 Discussion
 References
 

  1. Albores-Saavedra J, Poucell S, Rodriguez-Martinez HA. 1972 Primary carcinoid of the uterine cervix. Pathologia. 10:185–193.
  2. Albores-Saavedra J, Gersell D, Gilks B, et al. 1997 Terminology of endocrine tumors of the uterine cervix. Results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute. Arch Pathol Lab Med. 121:34–39.[Medline]
  3. Berthelot P, Benhamon JP, Fauvert R. 1961 Hypercorticisme et cancer de l’uterus. Nouv Presse Med. 69:189–190.
  4. Jones HW, Plymate S, Gluck FB, Miles PA, Greene JF Jr. 1976 Small cell nonkeratinizing carcinoma of the cervix associated with ACTH production. Cancer. 38:1629–1635.[CrossRef][Medline]
  5. Lojek MA, Fer MF, Kasselberg AG, et al. 1980 Cushing’s syndrome with small cell carcinoma of the uterine cervix. Am J Med. 69:140–144.[CrossRef][Medline]
  6. Pazdur R, Bonomi P, Slayton R, et al. 1981 Neuroendocrine carcinoma of the cervix: implications for staging and therapy. Gynecol Oncol. 12:120–128.[CrossRef][Medline]
  7. Kiang DT, Bauer GE, Kennedy BJ. 1973 Immunoassayable insulin in carcinoma of the cervix associated with hypoglycemia. Cancer. 31:801–805.[CrossRef][Medline]
  8. Matsuyama M, Inoue T, Ariyoshi Y, et al. 1979 Argyrophil cell carcinoma of the uterine cervix with ectopic production of ACTH, ß-MSH, serotonin, histamine and amylase. Cancer. 44:1813–1823.[CrossRef][Medline]
  9. Driessens J, Clay A, Adenis L, Demaille A. 1964 Tumeur cervico-uterine et syndrome biologique de carcinoidose. Arch Anat Pathol. 12:200–203.
  10. Stockdale AD, Leader M, Phillips RH, Henry K. 1986 The carcinoid syndrome and multiple hormone secretion associated with a carcinoid tumour of the uterine cervix. Case report. Br J Obstet Gynecol. 93:397–401.[Medline]
  11. Albores-Saavedra J, Rodriguez-Martinez HA, Larraza-Hernandez O. 1979 Carcinoid tumours of the cervix. Pathol Annu. 14:273–291.
  12. Tateishi R, Wada A, Hayakawa K, Hongo J, Ishii S, Terakawa N. 1975 Argyrophil cell carcinomas (apudomas) of the uterine cervix. Light and electron microscopic observations of 5 cases. Virchows Arch Pathol Anat Histol. 366:257–274.[CrossRef]
  13. Fox H, Kazzaz B, Langley FA. 1964 Argyrophil and argentaffin cells in the female genital tract and in ovarian mucinous cysts. J Pathol Bacteriol. 88:479–488.[CrossRef][Medline]
  14. Gould VE, Linnoila RI, Memoli VA, Warren WH. 1983 Neuroendocrine cells and neuroendocrine neoplasms of the lung. Pathol Annu. 18:287–330.
  15. Gilks CB, Young RH, Gersell DJ, Clement PB. 1997 Large cell carcinoma of the uterine cervix: a clinicopathologic study of 12 cases. Am J Surg Pathol. 21;905–914.
  16. Albores-Saavedra J, Larraza O, Poucell S, Rodriguez-Martinez HA. 1976 Carcinoid of the uterine cervix: additional observation on a new tumor entity. Cancer. 38:2328–2342.[CrossRef][Medline]
  17. Barret RJ, Davos I, Leuchter RS, Lagasse LD. 1987 Neuroendocrine features in poorly differentiated and undifferentiated carcinomas of the cervix. Cancer. 60:2325–2330.[CrossRef][Medline]
  18. Savargaonkar PR, Hale RJ, Mutton A, Manning V, Buckley CH. 1996 Neuroendocrine differentiation in cervical carcinoma. J Clin Pathol. 49:139–141.[Abstract/Free Full Text]
  19. Ueda G, Yamasaki M, Inoue M, et al. 1984 Immunohistochemical demonstration of peptide hormones in cervical adenocarcinomas with argyrophil cells. Int J Gynecol Pathol. 2:373–379.[Medline]
  20. Azzopardi JG, Hou LT. 1965 Intestinal metaplasia with argentaffin cells in cervical adenocarcinoma. J Pathol Bacteriol. 90:686–690.[CrossRef][Medline]
  21. Kaku T, Enjoji M. 1983 Extremely well-differentiated adenocarcinoma (adenoma malignum) of the cervix. Int J Gynecol Pathol. 2:28–41.[Medline]
  22. Scully RE, Aguirre P, DeLellis RA. 1984 Argyrophilia, serotonin, and peptide hormones in the female genital tract and its tumors. Int J Gynecol Pathol. 3:51–70.[Medline]
  23. Silva EG, Kott MM, Ordonez NG. 1984 Endocrine carcinoma intermediate cell type of the uterine cervix. Cancer. 54:1705–1713.[CrossRef][Medline]
  24. Muraoka S, Takahashi, T, Ando M, Nishikawa Y, Fujita M, Shimoda A. 1987 Minute carcinoid tumor of the uterine cervix associated with microinvasive adenocarcinoma, with reference to its histogenesis. Acta Pathol Jpn. 37:1183–1198.[Medline]
  25. Chan JK, Tsui WM, Tung SY, Ching RC. 1989 Endocrine cell hyperplasia of the uterine cervix. A precursor of neuroendocrine carcinoma of the cervix ? Am J Clin Pathol. 92:825–830.[Medline]
  26. Gersell DJ, Mazoujian G, Mutch DG, Mutch DG, Rudloff MA. 1988 Small-cell undifferentiated carcinoma of the cervix. Am J Surg Pathol. 12:684–698.[Medline]
  27. Walker AN, Mills SE, Taylor PT. 1988 Cervical neuroendocrine carcinoma: a clinical and light microscopic study of 14 cases. Int J Gynecol Pathol. 7:64–74.[Medline]
  28. Husain AN, Gattuso P, Abraham K, Castelli MJ. 1989 Synchronous adenocarcinoma and carcinoid of the uterine cervix: immunohistochemical study of a case and review of the literature. Gynecol Oncol. 33:125–128.[CrossRef][Medline]
  29. Tormey WP, Fitzgerald RJ. 1995 The clinical and laboratory correlates of an increased urinary 5-hydroxyindole-acetic acid. Postgrad Med J. 71:542–545.[Abstract]
  30. Feldman J, O’Dorisio TM. 1986 Role of neuropeptides and serotonin in the diagnosis of carcinoid tumors. Am J Med 81(Suppl 6B):41–48.
  31. Kulke MH, Mayer RJ. 1999 Carcinoid tumors. N Engl J Med. 340:858–868.[Free Full Text]
  32. Toki T, Katayama Y, Motoyama T. 1996 Small-cell neuroendocrine carcinoma of the uterine cervix associated with micro-invasive squamous cell carcinoma and adenocarcinoma in situ. Pathol Int. 46:520–525.[Medline]
  33. Davis RB, Rosenberg JC. 1959 Carcinoid syndrome with normal 5-HIAA excretion. J Lab Clin Med. 54:804.
  34. Davis Z, Moertel CG, McIlrath DC. 1973 The malignant carcinoid syndrome. Surg Gynecol Obstet. 137:637–644.[Medline]
  35. Robertson JIS, Peart WS, Andrews TM. 1962 The mechanism of facial flushes in the carcinoid syndrome. Q J Med. 31:103–123.[Free Full Text]
  36. Post RC, Cohen T, Blaustein AU, Shenker L. 1966 Carcinoid tumor metastatic to the cervix and corpus uteri. Obstet Gynecol. 27:171.[Free Full Text]
  37. Modlin M, Cornelius E, Lawton GP. 1995 Use of an isotopic somatostatin probe to image gut endocrine tumors. Arch Surg. 130:367–373.[Abstract]
  38. Tsukamoto N, Hirakawa T, Matsukuma K, et al. 1989 Carcinoma of the uterine cervix with variegated histological patterns and calcitonin production. Gynecol Oncol. 33:395–399.[CrossRef][Medline]
  39. Inoue T, Matsuyama, N, Yamaguchi K, Abe K, Chihara T. A cervical carcinoma with ectopic production of somatostatin, calcitonin, gastrin, vasoactive intestinal polypeptide (VIP) and pancreatic polypeptide (PP). Proc 39th Annual Meeting of the Japanese Cancer Assoc., Tokyo, Japan, 1980, p 367.
  40. Warner TFCS. 1978 Carcinoid tumor of the uterine cervix. J Clin Pathol. 31:990–995.[Abstract/Free Full Text]
  41. O’Hanlan KA, Goldberg GL, Jones JG, Runowicz CD, Ehrlich L, Rodriguez-Rodriguez L. 1991 Adjuvant therapy for neuroendocrine small cell carcinoma of the cervix: review of the literature. Gynecol Oncol. 43:167–172.[CrossRef][Medline]
  42. Oberg K, Eriksson B, Janson ET. 1994 Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neurodendocrine gut and pancreatic tumors. Digestion. 55(Suppl 3):64–69.
  43. Janson ET, Oberg K. 1993 Long-term management of the carcinoid syndrome: treatment with octreotide alone and in combination with {alpha}-interferon. Acta Oncol. 32:225–229.[Medline]
  44. Ueda G, Yamasaki M. 1992 Neuroendocrine carcinoma of the uterus. Curr Top Pathol. 85:309–335.[Medline]



This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
K. Miehle, A. Tannapfel, P. Lamesch, G. Borte, E. Schenker, R. Kluge, R. A. Ott, V. Wiechmann, M. Koch, W. Kassahun, et al.
Pancreatic Neuroendocrine Tumor with Ectopic Adrenocorticotropin Production upon Second Recurrence
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3731 - 3736.
[Abstract] [Full Text] [PDF]

Home page
 RadioGraphicsHome page
Y. Okamoto, Y. O. Tanaka, M. Nishida, H. Tsunoda, H. Yoshikawa, and Y. Itai
MR Imaging of the Uterine Cervix: Imaging-Pathologic Correlation
RadioGraphics, March 1, 2003; 23(2): 425 - 445.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Koch, C. A.
Right arrow Articles by Clement, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Koch, C. A.
Right arrow Articles by Clement, S. C.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Medline Plus Health Information
*Carcinoid Tumors
*Cervical Cancer

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals